Literature DB >> 7608173

Human hepatoma cell mutant defective in cell surface protein trafficking.

R J Stockert1, B Potvin, L Tao, P Stanley, A W Wolkoff.   

Abstract

To isolate a mutant liver cell defective in the endocytic pathway, a selection strategy using toxic ligands for two distinct membrane receptors was devised. Ovalbumin-gelonin and asialoorosomucoid (ASOR)-gelonin were incubated with mutagenized HuH-7 cells, and a rare survivor termed trafficking mutant 1 (Trf1) was isolated. Trf1 cells were stably 3-fold more resistant than the parental HuH-7 to both toxic conjugates. The anterograde steps of intracellular endocytic processing of ASOR, including internalization, endosomal acidification, and ligand degradation, were unaltered in Trf1 cells. In contrast, retrograde diacytosis of asialoglycoprotein receptor (ASGR).ASOR complex back to the cell surface was enhanced by about 250%. Selective labeling revealed an approximately 46% reduction in cell surface-associated ASGR in Trf1 cells, although their total cellular ASGR content was essentially equivalent to that in HuH-7. Similar results were obtained with the transferrin receptor. Binding of 125I-ASOR and 125I-transferrin was reduced in Trf1 cells to 49 +/- 2.5% and 30 +/- 2%, respectively, of HuH-7 cells. The methionine transporter was also reduced in Trf1 cells, as revealed by a 2-fold reduction in Vmax with no change in apparent Km. Pretreatment with monensin, sodium azide, or colchicine reduced surface binding of 125I-ASOR in HuH-7 cells by 50% but had no effect on binding to Trf1 cells. This result is predicted for a cell that expresses only State 1 ASGRs, which are resistant to modulation by metabolic and cytoskeletal inhibitors in contrast to State 2, which are responsive to these agents (Weigel, P. H., and Oka, J. A. (1984) J. Biol. Chem. 259, 1150-1154). The Trf1 mutant, having lost the ability to express State 2 receptors, provides genetic evidence for the existence of these two receptor subpopulations and an approach to identifying the biochemical mechanism by which they are generated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608173     DOI: 10.1074/jbc.270.27.16107

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Single vesicle analysis of endocytic fission on microtubules in vitro.

Authors:  John W Murray; Souvik Sarkar; Allan W Wolkoff
Journal:  Traffic       Date:  2008-02-15       Impact factor: 6.215

2.  Rab1a regulates sorting of early endocytic vesicles.

Authors:  Aparna Mukhopadhyay; Jose A Quiroz; Allan W Wolkoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-01-09       Impact factor: 4.052

3.  Proteomic analysis of endocytic vesicles: Rab1a regulates motility of early endocytic vesicles.

Authors:  Aparna Mukhopadhyay; Edward Nieves; Fa-Yun Che; Jean Wang; Lianji Jin; John W Murray; Kristie Gordon; Ruth Hogue Angeletti; Allan W Wolkoff
Journal:  J Cell Sci       Date:  2011-02-08       Impact factor: 5.285

4.  An epitope of the Semliki Forest virus fusion protein exposed during virus-membrane fusion.

Authors:  A Ahn; M R Klimjack; P K Chatterjee; M Kielian
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 5.  Impact of asialoglycoprotein receptor deficiency on the development of liver injury.

Authors:  Serene M L Lee; Carol A Casey; Benita L McVicker
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

6.  New liver cell mutants defective in the endocytic pathway.

Authors:  Richard J Stockert; Barry Potvin; Sangeeta Nath; Allan W Wolkoff; Pamela Stanley
Journal:  Biochim Biophys Acta       Date:  2007-04-14

7.  Microtubule and motor-dependent endocytic vesicle sorting in vitro.

Authors:  E Bananis; J W Murray; R J Stockert; P Satir; A W Wolkoff
Journal:  J Cell Biol       Date:  2000-10-02       Impact factor: 10.539

8.  Human liver cell trafficking mutants: characterization and whole exome sequencing.

Authors:  Fei Yuan; Erik L Snapp; Phyllis M Novikoff; Sylvia O Suadicani; David C Spray; Barry Potvin; Allan W Wolkoff; Pamela Stanley
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.